62 related articles for article (PubMed ID: 38688773)
41. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.
Yu EY; Gillessen S; Mottet N
Eur Urol Focus; 2019 Mar; 5(2):162-164. PubMed ID: 30287277
[TBL] [Abstract][Full Text] [Related]
42. Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms.
Baboudjian M; Hashim H; Bhatt N; Creta M; De Nunzio C; Gacci M; Herrmann T; Karavitakis M; Malde S; Moris L; Netsch C; Rieken M; Sakalis V; Schouten N; Tutolo M; Cornu JN
Eur Urol; 2024 Apr; ():. PubMed ID: 38644139
[TBL] [Abstract][Full Text] [Related]
43. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
[TBL] [Abstract][Full Text] [Related]
44. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A
Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144
[TBL] [Abstract][Full Text] [Related]
45. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Rouprêt M; Seisen T; Birtle AJ; Capoun O; Compérat EM; Dominguez-Escrig JL; Gürses Andersson I; Liedberg F; Mariappan P; Hugh Mostafid A; Pradere B; van Rhijn BWG; Shariat SF; Rai BP; Soria F; Soukup V; Wood RG; Xylinas EN; Masson-Lecomte A; Gontero P
Eur Urol; 2023 Jul; 84(1):49-64. PubMed ID: 36967359
[TBL] [Abstract][Full Text] [Related]
46. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance.
Ploussard G; Roubaud G; Barret E; Beauval JB; Brureau L; Créhange G; Dariane C; Fiard G; Fromont G; Gauthé M; Renard-Penna R; Rozet F; Ruffion A; Sargos P; Mathieu R; Rouprêt M;
Prog Urol; 2022 Nov; 32(15):1373-1419. PubMed ID: 36400484
[TBL] [Abstract][Full Text] [Related]
47. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.
Sheehan B; Guo C; Neeb A; Paschalis A; Sandhu S; de Bono JS
Eur Urol Focus; 2022 Sep; 8(5):1157-1168. PubMed ID: 34167925
[TBL] [Abstract][Full Text] [Related]
48. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
49. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
Loeb S; Giri VN
Eur Urol Oncol; 2021 Feb; 4(1):1-9. PubMed ID: 33390340
[TBL] [Abstract][Full Text] [Related]
50. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort
Witjes JA; Babjuk M; Bellmunt J; Bruins HM; De Reijke TM; De Santis M; Gillessen S; James N; Maclennan S; Palou J; Powles T; Ribal MJ; Shariat SF; Der Kwast TV; Xylinas E; Agarwal N; Arends T; Bamias A; Birtle A; Black PC; Bochner BH; Bolla M; Boormans JL; Bossi A; Briganti A; Brummelhuis I; Burger M; Castellano D; Cathomas R; Chiti A; Choudhury A; Compérat E; Crabb S; Culine S; De Bari B; De Blok W; J L De Visschere P; Decaestecker K; Dimitropoulos K; Dominguez-Escrig JL; Fanti S; Fonteyne V; Frydenberg M; Futterer JJ; Gakis G; Geavlete B; Gontero P; Grubmüller B; Hafeez S; Hansel DE; Hartmann A; Hayne D; Henry AM; Hernandez V; Herr H; Herrmann K; Hoskin P; Huguet J; Jereczek-Fossa BA; Jones R; Kamat AM; Khoo V; Kiltie AE; Krege S; Ladoire S; Lara PC; Leliveld A; Linares-Espinós E; Løgager V; Lorch A; Loriot Y; Meijer R; Mir MC; Moschini M; Mostafid H; Müller AC; Müller CR; N'Dow J; Necchi A; Neuzillet Y; Oddens JR; Oldenburg J; Osanto S; J G Oyen W; Pacheco-Figueiredo L; Pappot H; Patel MI; Pieters BR; Plass K; Remzi M; Retz M; Richenberg J; Rink M; Roghmann F; Rosenberg JE; Rouprêt M; Rouvière O; Salembier C; Salminen A; Sargos P; Sengupta S; Sherif A; Smeenk RJ; Smits A; Stenzl A; Thalmann GN; Tombal B; Turkbey B; Lauridsen SV; Valdagni R; Van Der Heijden AG; Van Poppel H; Vartolomei MD; Veskimäe E; Vilaseca A; Rivera FAV; Wiegel T; Wiklund P; Williams A; Zigeuner R; Horwich A
Eur Urol; 2020 Feb; 77(2):223-250. PubMed ID: 31753752
[TBL] [Abstract][Full Text] [Related]
51. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training.
de Rooij M; Israël B; Tummers M; Ahmed HU; Barrett T; Giganti F; Hamm B; Løgager V; Padhani A; Panebianco V; Puech P; Richenberg J; Rouvière O; Salomon G; Schoots I; Veltman J; Villeirs G; Walz J; Barentsz JO
Eur Radiol; 2020 Oct; 30(10):5404-5416. PubMed ID: 32424596
[TBL] [Abstract][Full Text] [Related]
52. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
Cathomas R; Lorch A; Bruins HM; Compérat EM; Cowan NC; Efstathiou JA; Fietkau R; Gakis G; Hernández V; Espinós EL; Neuzillet Y; Ribal MJ; Rouanne M; Thalmann GN; van der Heijden AG; Veskimäe E; Alfred Witjes J; Milowsky MI;
Eur Urol; 2022 Jan; 81(1):95-103. PubMed ID: 34742583
[TBL] [Abstract][Full Text] [Related]
53. [Advanced prostate cancer: sequence of androgen receptor-targeted substances and chemotherapy determines long-term survival].
Wülfing C; Goebell PJ; Eichenauer R; Lange C; Machtens S; Schwentner C; Todenhöfer T; Tauber R; Schostak M
Urologe A; 2021 Feb; 60(2):212-221. PubMed ID: 33346857
[TBL] [Abstract][Full Text] [Related]
54. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
55. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Sood A; Kishan AU; Evans CP; Feng FY; Morgan TM; Murphy DG; Padhani AR; Pinto P; Van der Poel HG; Tilki D; Briganti A; Abdollah F
Eur Urol Oncol; 2024 Feb; 7(1):27-43. PubMed ID: 37423774
[TBL] [Abstract][Full Text] [Related]
56. To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?
Caffo O; Maines F; Kinspergher S; Veccia A; Messina C
Expert Rev Anticancer Ther; 2021 Apr; 21(4):389-400. PubMed ID: 33245666
[No Abstract] [Full Text] [Related]
57. [EAU guidelines on testicular cancer: 2011 update. European Association of Urology].
Albers P; Albrecht W; Algaba F; Bokemeyer C; Cohn-Cedermark G; Fizazi K; Horwich A; Laguna MP;
Actas Urol Esp; 2012 Mar; 36(3):127-45. PubMed ID: 22188753
[TBL] [Abstract][Full Text] [Related]
58. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Tilki D; van den Bergh RCN; Briers E; Van den Broeck T; Brunckhorst O; Darraugh J; Eberli D; De Meerleer G; De Santis M; Farolfi A; Gandaglia G; Gillessen S; Grivas N; Henry AM; Lardas M; J L H van Leenders G; Liew M; Linares Espinos E; Oldenburg J; van Oort IM; Oprea-Lager DE; Ploussard G; Roberts MJ; Rouvière O; Schoots IG; Schouten N; Smith EJ; Stranne J; Wiegel T; Willemse PM; Cornford P
Eur Urol; 2024 Apr; ():. PubMed ID: 38688773
[TBL] [Abstract][Full Text] [Related]
59. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Brunckhorst O; Darraugh J; Eberli D; De Meerleer G; De Santis M; Farolfi A; Gandaglia G; Gillessen S; Grivas N; Henry AM; Lardas M; van Leenders GJLH; Liew M; Linares Espinos E; Oldenburg J; van Oort IM; Oprea-Lager DE; Ploussard G; Roberts MJ; Rouvière O; Schoots IG; Schouten N; Smith EJ; Stranne J; Wiegel T; Willemse PM; Tilki D
Eur Urol; 2024 Apr; ():. PubMed ID: 38614820
[TBL] [Abstract][Full Text] [Related]
60. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
